Testing Etavopivat for Pain Crises in Sickle Cell Disease
Tests etavopivat or a placebo in teenagers and adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Key facts
- Where
- 's-Gravenhage, Amsterdam, Rotterdam, and Utrecht, NetherlandsSee the 4 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with sickle cell disease who have had several documented pain crises (vaso-occlusive crises) in the past year.
- Age
- 12 years or older
- Sex
- Men and women
- Disease stage
- Confirmed sickle cell disease (HbSS, HbSβ0-thalassemia or other sickle cell variants), with 2-15 documented vaso-occlusive crises in the 12 months before screening, and haemoglobin between 5.0 and 10.0 g/dL (50 to 100 g/L).
- Earlier treatment
- Cannot have used voxelotor or similar medicine within 28 days, a selectin antagonist (such as crizanlizumab) within 28 days or 5 half-lives, or erythropoietin within 28 days. Cannot have had prior cell-based therapy such as a stem cell transplant or gene therapy.
- Biomarker or test result
- Sickle cell disease genotype (HbSS, HbSβ0-thalassemia or other variants) shown by past or screening lab tests. Haemoglobin 5.0 to 10.0 g/dL.
Main reasons for not taking part
- Regular scheduled blood transfusions, or 6 or more transfusions in the past 12 months
- Prior cell-based therapy (stem cell transplant, gene therapy)
- Liver problems (ALT above 4.0 × ULN or direct bilirubin above 3.0 × ULN)
- Severe kidney problems or chronic dialysis
- Walking distance below 100m on the 6-minute walk test at screening
Read by machine on 12 November 2026.
Where in Netherlands
- Haga Hospital's-Gravenhage, NetherlandsTaking people
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT06612268EU 2023-509175-16-00
- Record updated
- 17 September 2026
- Original description
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.Read full original descriptionShow less
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Inclusion: Male or female; Age 12 years or above at the time of signing the informed consent; Confirmed diagnosis of sickle cell disease: Documentation of sickle cell disease (SCD) genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing or screening test results from central laboratory. Molecular genotyping is not required. SCD genotype may be determined from the results of haemoglobin (Hb) electrophoresis, high-performance liquid chromatography (HPLC) or similar testing. Note that Hb electrophoresis is performed by the central laboratory at screening; Have 2-15 episodes of documented vaso occlusive crises (VOC) within the 12 months prior to screening. Documentation must exist in the participant's medical record prior to randomisation. Events based solely on participant recall without supporting documentation should not be counted towards eligibility; Hb greater than or equal to (≥) 5.0 and less than or equal to (≤) 10.0 g/dL (greater than or equal to (≥) 50 and less than or equal to (≤) 100 grams per litre [g/L]) at screening.
Exclusion: Use of voxelotor or similar agent within 28 days prior to starting study treatment or anticipated need for this agent during the study; Use of a selectin antagonist (e.g., crizanlizumab, monoclonal antibody or small molecule) within 28 days or 5 half-lives (whichever is longer) prior to starting study treatment or anticipated need for such agents during the study; Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or greater than or equal to 6 transfusion events within the previous 12 months prior to screening (i.e., an average of 1 transfusion event every 60 days); Receiving or use of concomitant medications that are strong or moderate inducers of CYP3A4 (cytochrome p450 3a4) within 2 weeks of starting study treatment or anticipated need for such agents during the study; Receipt of prior cellular-based therapy (e.g., haematopoietic cell transplant, gene modification therapy); Participants who have received an RBC transfusion for any reason within 60 days of the screening period or 60 days of the randomisation day are only eligible if HbA (adult haemoglobin) less than 10% by Hb electrophoresis is documented prior to starting study treatment; Hepatic dysfunction characterized by:; Alanine aminotransferase (ALT) greater than 4.0 × upper limit of normal (ULN) or; Direct bilirubin greater than 3.0 × ULN; Severe renal dysfunction (estimated glomerular filtration rate [eGFR] at screening, calculated by the central laboratory greater than 30 mL/min/1.73 m\^ 2) or on chronic dialysis; Use of erythropoietin or other haematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study; Participants who are not taking or are unable to take antimalarial prophylaxis at the time of consent and during the study if they live in areas of endemic malaria where prophylaxis is recommended; Travelled distance on standardized 6MWT below 100m at screening.